ST6GAL1 and prostate carcinoma: In prostate cancer, ST6GAL1-mediated aberrant sialylation promotes tumour growth and is linked to disease progression, but the role of ST6GAL1 and sialylated N-glycans in prostate cancer metastasis has not yet been investigated.